210 related articles for article (PubMed ID: 22233255)
1. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Nan XP; Zhang Y; Yu HT; Sun RL; Peng MJ; Li Y; Su WJ; Lian JQ; Wang JP; Bai XF
Viral Immunol; 2012 Feb; 25(1):21-8. PubMed ID: 22233255
[TBL] [Abstract][Full Text] [Related]
2. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA.
Yan Z; Zhou J; Zhang M; Fu X; Wu Y; Wang Y
Mol Med Rep; 2014 May; 9(5):2024-30. PubMed ID: 24626572
[TBL] [Abstract][Full Text] [Related]
4. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
6. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
7. [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
Pan XC; Yang F; Chen M
Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):885-8. PubMed ID: 19105929
[TBL] [Abstract][Full Text] [Related]
8. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
Suh DJ; Um SH; Herrmann E; Kim JH; Lee YS; Lee HJ; Lee MS; Lee YJ; Bao W; Lopez P; Lee HC; Avila C; Zeuzem S
Antimicrob Agents Chemother; 2010 Mar; 54(3):1242-7. PubMed ID: 20028815
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
TrehanPati N; Kotillil S; Hissar SS; Shrivastava S; Khanam A; Sukriti S; Mishra SK; Sarin SK
J Clin Immunol; 2011 Jun; 31(3):509-20. PubMed ID: 21305387
[TBL] [Abstract][Full Text] [Related]
11. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
12. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B.
Jiang X; Zhang M; Lai Q; Huang X; Li Y; Sun J; Abbott WG; Ma S; Hou J
PLoS One; 2011; 6(12):e28871. PubMed ID: 22194934
[TBL] [Abstract][Full Text] [Related]
13. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.
Peng G; Li S; Wu W; Sun Z; Chen Y; Chen Z
Immunology; 2008 Jan; 123(1):57-65. PubMed ID: 17764450
[TBL] [Abstract][Full Text] [Related]
14. Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
Hou FQ; Wu XJ; Wang Y; Chen J; Liu YZ; Ren YY; Song G; Ding YP; Yu M; Wang GQ
J Viral Hepat; 2013 Apr; 20 Suppl 1():18-26. PubMed ID: 23458521
[TBL] [Abstract][Full Text] [Related]
15. Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B.
Pan X; Yao W; Fu J; Liu M; Li L; Gao X
Acta Virol; 2012; 56(1):31-8. PubMed ID: 22404607
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
Arasli M; Ustundag Y; Delikanli B; Harmandar F; Buyukuysal C
Hepatogastroenterology; 2012 May; 59(115):851-7. PubMed ID: 22193343
[TBL] [Abstract][Full Text] [Related]
17. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
18. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Liang J; Han T; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
[TBL] [Abstract][Full Text] [Related]
19. Telbivudine: a review of its use in compensated chronic hepatitis B.
McKeage K; Keam SJ
Drugs; 2010 Oct; 70(14):1857-83. PubMed ID: 20836578
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis B: focus on telbivudine.
Lui YY; Chan HL
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):259-68. PubMed ID: 19344240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
